ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

オクトレオチド酢酸塩

Octreotide

HCID 448601
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
83150-76-9
標準SMILES
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O
InChIKey
DEQANNDTNATYII-OULOTJBUSA-N
分子式
C49H66N10O10S2
平均分子量
1,019.2 g/mol
単同位体質量
1,018.44048069

概要

Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management. Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone. Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas). In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.

名称と識別子

優先名称
Octreotide
IUPAC
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
現地名
オクトレオチド酢酸塩
英語名
Octreotide acetate
分子式
C49H66N10O10S2
分子量
1019.24

名称と別名

Octreotide83150-76-9OctreotidaOctreotidumRWM8CCW8GPSMS-201-995SMS995SMS-995Compound 201995Octreotide Acetate SaltDRG-0115Sandoz 201995
名称をさらに表示
D-Phe-Cys(1)-Phe-D-Trp-Lys-Thr-Cys(1)-N-[(1R,2R)-1-(ヒドロキシメチル)-2-ヒドロキシプロピル]-NH2オクトレオチドD-Phe-L-Cys(1)-L-Phe-D-Trp-L-Lys-L-Thr-L-Cys(1)-N-[(1R,2R)-2-ヒドロキシ-1-(ヒドロキシメチル)プロピル]-NH2オクトレオチド酢酸塩 (JAN)(4R,7S,10S,13R,16S,19R)-19-[(2R)-2-アミノ-3-フェニルプロパンアミド]-10-(4-アミノブチル)-16-ベンジル-N-[(2R,3R)-1,3-ジヒドロキシブタン-2-イル]-7-[(1R)-1-ヒドロキシエチル]-13-[(1H-インドール-3-イル)メチル]-6,9,12,15,18-ペンタオキソ-1,2-ジチア-5,8,11,14,17-ペンタアザシクロイコサン-4-カルボキサミドctreotideDARAMONOLGMP(CFDA)OXTREOTIDELongastatinOctreotide acetateOctreotode AcetateOcetreotide, AcetateOctreotide oral filmOctreotide Acetate(b)
SAN 201995SM 201995D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfideDTXSID0048682SMS 201995L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2-7)-disulfide, (R-(R*,R*))-CHEBI:7726RefChem:59031

物性

構造計算による物性

XLogP
1
極性表面積
383 Ų
水素結合供与体数
13
水素結合受容体数
14
回転可能結合数
17
重原子数
71
形式電荷
0
複雑度
1,740

実験および物理化学的性質

Human Drugs · 3 件

Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents, Hormonal; Gastrointestinal Agents

EMA approved medicines: Human medicine

Medicines for disorders of the pituitary hormone system

Melting Point153-156

物理化学的性質

融点
140 °C · >140°C (dec.)
沸点
1447.2 · 1447.2±65.0 °C(Predicted)
比重(密度)
1.39 · 1.39±0.1 g/cm3(Predicted)
貯蔵温度
-20 °C · -20°C
溶解性
2 O: · H2O: 可溶
酸解離定数(Pka)
12.6 · 12.60±0.70(Predicted)
外見
個体
色
ホワイトからオフホワイト
水溶解度
1.2 mg/ml · Soluble to 1.20 mg/ml in water
安定性
吸湿性
InChIKey
DEQANNDTNATYII-MEUDYGGUSA-N
CAS データベース
83150 · 83150-76-9

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

危険有害性情報

Regulatory InformationOctreotide: Does not have an individual approval but may be used under an appropriate group standard

毒性情報

Hepatotoxicity · 1 件

Mild, transient, asymptomatic elevations in serum aminotransferase levels occur in a small proportion of patients receiving octreotide, and in some individuals the elevations are persistent and worsen over time and may require drug discontinuation. In addition, several instances of acute, clinically apparent liver injury attributable to octreotide have been described. The onset is generally within 1 to 6 months of starting therapy and injury may be more frequent with higher doses. Most cases of liver injury associated with octreotide therapy have been asymptomatic and anicteric, and marked by prominent elevations in serum ALT and AST with normal or near normal serum alkaline phosphatase, GGT and bilirubin. In some instances, however, jaundice has arisen, particularly with rechallenge. There have been no instances of acute liver failure or vanishing bile duct syndrome associated with octreotide, and a characteristic feature of the injury is the rapidity of improvement upon stopping the injections or infusions. Several instances of marked aminotransferase elevations with rapid improvements on stopping have been reported in newborns and infants with congenital hyperinsulinemia who were treated with continuous infusions of high doses of octreotide.

Adverse Effects · 1 件

* Gastrointestinal abnormalities (34% to 61%) are transient and usually mild to moderate. They include diarrhea, nausea, abdominal discomfort, gallbladder abnormalities, such as cholelithiasis and microlithiasis, biliary sediment and sludge due to alteration of fat absorption, and possibly by decreasing motility of the gallbladder.

Toxicity Summary · 1 件

Limited studies have assessed octreotide toxicity. However, isolated studies have shown a mild degree of bone marrow suppression and impairment in spermatogenesis due to inhibition of serum inhibin B and concomitant increase in FSH in supratherapeutic doses. There is a need to conduct significantly larger studies and trials to define and establish the therapeutic index of octreotide and identify its toxic effects and its management.

化学と産業

薬理情報

ATC Code · 3 件

H - Systemic hormonal preparations, excl. sex hormones and insulins

QH - Systemic hormonal preparations, excl. sex hormones and insulin

H01CB02

Protein BindingApproximately 65% of the dose is bound in the plasma to lipoproteins and albumin.
Pharmacodynamics · 1 件

Octreotide mimics the naturally occurring hormone known as somatostatin. Like somatostatin, it demonstrates activity against growth hormone and glucagon, treating the disordered tissue growth and insulin regulation in patients with acromegaly. In addition, octreotide relieves the flushing and diarrhea associated with gastrointestinal tumors by reducing splanchnic blood flow and various gastrointestinal hormones associated with diarrhea. Product labeling warns that octreotide may reduce gallbladder contractility, bile secretion, and the release of thyroid-stimulating hormone (TSH) in healthy volunteers. In addition, reports of decreased vitamin B12 in patients treated with octreotide have been made. Ensure to monitor vitamin B12 levels in patients taking octreotide.

Mechanism of Action · 1 件

Octreotide binds to somatostatin receptors coupled to phospholipase C through G proteins and leads to smooth muscle contraction in the blood vessels. Downstream effects that stimulate phospholipase C, the production of 1, 4,5-inositol triphosphate, and action on the L-type calcium channels lead to the inhibition of growth hormone, treating the various growth-hormone and metabolic effects of acromegaly. Octreotide's suppression of luteinizing hormone (LH), reduction in splanchnic blood flow, and inhibition of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide provide relief for the gastrointestinal and flushing symptoms of carcinoid and/or VIPoma tumors.

Biological Half-Life · 1 件

After a subcutaneous dose, the plasma half-life is estimated to be 0.2 hours. The average elimination half-lives for subcutaneous and oral administration ranged from 2.3 - 2.7 hours and did not differ significantly. One pharmacokinetic study revealed a plasma half-life ranging from 72-113 minutes.

関連反応

8 件
反応記録を作成
HRID 77252 の反応式
HRID 77252反応物として
HRID 221184 の反応式
HRID 221184反応物として
HRID 539413 の反応式
HRID 539413生成物として
HRID 1395929 の反応式
HRID 1395929生成物として
HRID 1473729 の反応式
HRID 1473729生成物として反応物として
HRID 1735639 の反応式
HRID 1735639反応物として
HRID 1797776 の反応式
HRID 1797776生成物として反応物として
HRID 2424242 の反応式
HRID 2424242生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
83150-76-9
PubChem CID
448601
DTXSID
DTXSID0048682
ChEMBL
CHEMBL1680
UNII
RWM8CCW8GP
Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

octreotide

DILI Positive

Intravenous

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
3
Metabolism/MetabolitesOctreotide has been reported to be heavily metabolized in the liver.
FDA Pharmacological Classification · 6 件

RWM8CCW8GP

OCTREOTIDE

Established Pharmacologic Class [EPC] - Somatostatin Analog

Mechanisms of Action [MoA] - Somatostatin Receptor Agonists

Octreotide is a Somatostatin Analog. The mechanism of action of octreotide is as a Somatostatin Receptor Agonist.

OCTREOTIDE

MeSH Pharmacological Classification · 2 件

Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion.

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Absorption, Distribution and Excretion · 4 件

After a subcutaneous dose, octreotide is absorbed completely upon administration. After the administration of an oral delayed-release capsule, peak concentrations were found to be 33% lower than after subcutaneous administration. The Cmax was attained at 1.67–2.5 hours after oral administration versus 30 minutes for the subcutaneous route. At 20 mg twice a day in patients with acromegaly, peak concentration was 2.5 mg/nL versus 5.30 ng/mL at 40 mg twice a day. AUC increases in proportion with the dose, regardless of the route.

About 32% of an oral octreotide dose is excreted into the urine and 30-40% is excreted by the liver into the feces.. About 11% of the unchanged parent drug is found in the urine, and 2% of the unchanged parent drug can be recovered in the feces.

In a pharmacokinetic study, the volume of distribution was 13.6 L in healthy volunteers. One pharmacokinetic study revealed a volume of distribution ranging from 18.1-30.4L after intravenous administration in healthy volunteers.

The total body clearance of octreotide is 7-10 L/h. One pharmacokinetic study revealed a total body clearance of 11.4 L/h.

用途と製造

UsesUse (kg) in USA (2002): 1
応用分野 · 4 件

用途ソマトスタチンアナログ先端巨大症・下垂体性巨人症の治療

説明Octreotide is a long-acting somatostatin analog indicated for symptomatic control in acromegaly and gastroenteropancreatic tumors. Other potential uses under investigation include diabetes, psoriasis and Alzheimer's disease.

使用Octreotide Acetate is the acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. It inhibits the secretion of growth hormone, glucagon, insulin, gastrin, vasoactive intestinal peptide, secretin, motilin and pancreatic polypeptide. Octreotide acetate was uses for the treatment of severe diarrhea and flushing associated with malignant carcinoid tumors, acromegaly, and diarrhea associated with VIPoma; and, then in 2010, for the treatment of neuroendocrine tumors.

一般的な説明Octreotide is a somatostatin analogue with D-Phe-Cys-Phe-D-Trp-Lys-ThrCys-Thr-OH amino acid sequence.

上流・下流製品情報

上流原料

オクトレオチド·酢酸塩N,N-ジメチルホルムアミドトリフルオロ酢酸酢酸アミルチオアニソールN,N'-ジシクロヘキシルカルボジイミドN,N-ジイソプロピルエチルアミンN,N'-ジイソプロピルカルボジイミドピペリジンL-THREONINOL1-ヒドロキシベンゾトリアゾール一水和物